CN114984063A - 皮肤外用剂组合物及功能性食品组合物 - Google Patents
皮肤外用剂组合物及功能性食品组合物 Download PDFInfo
- Publication number
- CN114984063A CN114984063A CN202210155151.9A CN202210155151A CN114984063A CN 114984063 A CN114984063 A CN 114984063A CN 202210155151 A CN202210155151 A CN 202210155151A CN 114984063 A CN114984063 A CN 114984063A
- Authority
- CN
- China
- Prior art keywords
- skin
- composition
- external
- extract
- rhodophyta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 235000013376 functional food Nutrition 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000284 extract Substances 0.000 claims abstract description 55
- 241000206572 Rhodophyta Species 0.000 claims abstract description 34
- 241000191967 Staphylococcus aureus Species 0.000 claims description 40
- 230000008591 skin barrier function Effects 0.000 claims description 29
- 239000002537 cosmetic Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 241001204967 Martensia jejuensis Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 244000005714 skin microbiome Species 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000004888 barrier function Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 42
- 241001474374 Blennius Species 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 12
- 244000005700 microbiome Species 0.000 description 11
- 241000191963 Staphylococcus epidermidis Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000304 virulence factor Substances 0.000 description 6
- 230000007923 virulence factor Effects 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 235000013757 Juglans Nutrition 0.000 description 5
- 241000758789 Juglans Species 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- -1 filaggrin Chemical compound 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 230000005808 skin problem Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 108010050327 trypticase-soy broth Proteins 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 101710092462 Alpha-hemolysin Proteins 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101710145796 Staphylokinase Proteins 0.000 description 2
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000003660 reticulum Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241001491753 Ceramium rubrum Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241000790338 Dictyococcus Species 0.000 description 1
- 241000199924 Dictyota Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 101150065015 spa gene Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种包含济州红网藻提取物作为有效成分的皮肤外用剂组合物及功能性食品组合物。
Description
技术领域
本发明涉及一种皮肤外用剂组合物及功能性食品组合物。
背景技术
皮肤屏障(skin barrier)是皮肤最外侧的角质层,可以称为皮肤最初的防御膜。皮肤屏障由角质细胞、和由诸如神经酰胺的脂质以及诸如丝聚蛋白的蛋白质等组成的角质细胞间质构成,它们形成多层结构,从而发挥完全的皮肤屏障作用。皮肤屏障的主要功能是阻止体液流失、毒素攻击和病原菌侵入。因此,皮肤屏障的损伤不仅仅是因为皮肤表层的单纯机械损伤,还可能是因为多种病原菌侵入而引起的严重免疫反应所导致。现有的治疗方法之一的抗生素疗法的局限性在于,不仅抑制皮肤有害菌(例如金黄色葡萄球菌Staphylococcus aureus),而且连同皮肤有益菌(例如表皮葡萄球菌Staphylococcusepidermidis)也被抑制,因而其效果不明显。因此,迫切需要开发一种不抑制皮肤共生有益菌而只抑制有害菌以改善皮肤屏障功能的材料。
微生物组(microbiome)是由表示微生物群落的微生物群(microbiota)和表示整组基因的基因组(genome)合成的词。相比微生物组,术语微生物群的侧重点在于微生物菌株本身,指栖息于人类身体并具有共生关系的微生物,而微生物组则是指脱离现有的个别微生物分析研究、基于基因组学的有关宿主生物与微生物间相互作用的研究和技术。众所周知,保持微生物组均衡会影响人体功能。最近,在化妆品、医学、制药领域正在对皮肤微生物组和皮肤屏障进行大量研究,并基于此积极研发化妆品、皮肤外用剂等。
发明内容
发明要解决的问题
一实施例提供一种不抑制皮肤共生有益菌而只抑制有害菌以改善皮肤屏障功能的皮肤外用剂组合物。
另一实施例提供一种不抑制皮肤共生有益菌而只抑制有害菌以改善皮肤屏障功能的功能性食品组合物。
用于解决问题的方案
一实施例提供包含济州红网藻提取物作为有效成分的皮肤外用剂组合物。
所述济州红网藻提取物的浓度可以为12.5μg/ml至200μg/ml。
所述皮肤外用剂组合物可以用于预防皮肤屏障损伤。
相对于所述皮肤外用剂组合物总重量,可以包含所述济州红网藻提取物0.001重量%至10重量%。
所述济州红网藻提取物可以缓解金黄色葡萄球菌(Staphylococcus aureus)的毒性。
所述济州红网藻提取物可以保持皮肤微生物组均衡。
所述济州红网藻提取物可以利用水、有机溶剂或它们的混合物提取。
所述有机溶剂可以为选自C1-C4的无水或含水乙醇、丙三醇、丙二醇、丁二醇、乙酸乙酯、己烷和三氯甲烷中的一种以上。
所述皮肤外用剂组合物可以制备成选自由化妆水、凝胶、水溶性液体、霜、粉、水包油(O/W)型和油包水(W/O)型组成的组中的剂型。所述皮肤外用剂组合物可以为化妆品组合物。
所述皮肤外用剂组合物可以为用于改善皮肤屏障功能的医药部外品组合物。
另一实施例提供一种用于改善皮肤屏障功能的功能性食品组合物,包含济州红网藻(Martensia jejuensis)提取物作为有效成分。
发明效果
根据一实施例的皮肤外用剂组合物防止皮肤细胞损伤,并保持皮肤微生物组均衡,从而对预防皮肤屏障损伤有效。
特别是对金黄色葡萄球菌有效,对于多种疾病诸如过敏性患者的皮肤,可以在皮肤屏障(skin barrier)损伤的状态下,极大地防止因金黄色葡萄球菌而导致的皮肤损伤,对诸如过敏性疾病的皮肤疾病患者极为有效。
另外,所述化妆品组合物包含天然物质作为有效成分,因而由合成物质所导致的副作用或危险度小。
附图说明
图1是示出根据一实施例的济州红网藻提取物对金黄色葡萄球菌的溶血活性的抑制程度的图表。
图2是示出经根据一实施例的济州红网藻提取物处理的实验组和未经处理的对照组中的表皮葡萄球菌(S.epidermidis)与金黄色葡萄球菌(S.aureus)的比率的图表。
图3是示出在根据一实施例的济州红网藻提取物的不同浓度下金黄色葡萄球菌的毒性因子相关基因表达量的图表。
图4是比较经根据一实施例的济州红网藻提取物处理的实验组与未经处理的对照组中的金黄色葡萄球菌引起皮肤细胞凋亡程度的图表。
具体实施方式
下面更详细地说明本发明。不过,这只是为了帮助理解本发明而进行具体描述,本发明的范围以权利要求书为基础进行解释。
根据一实施例的皮肤外用剂组合物包含济州红网藻提取物作为有效成分。
所述济州红网藻提取物可以由济州红网藻提取而得到。所述济州红网藻(Martensia jejuensis)是属于红藻类仙菜目的原产济州海域的韩国特有种。
所述济州红网藻提取物的浓度可以为12.5μg/ml至200μg/ml,例如,可以为25μg/ml至200μg/ml、50μg/ml至200μg/ml、100μg/ml至200μg/μl。济州红网藻提取物的浓度在上述范围内时,可以在皮肤屏障损伤的状态下极大地防止金黄色葡萄球菌引起的皮肤损伤。
相对于所述皮肤外用剂组合物总重量,可以包含所述济州红网藻提取物0.001重量%至10.0重量%,例如,可以包含0.01重量%至0.2重量%。
如果所述含量不足0.001重量%,则无法表现出有效的效果,如果超过10.0重量%,则存在变色、变臭等剂型稳定性的问题。
所述济州红网藻提取物可以缓解金黄色葡萄球菌(Staphylococcus aureus)的毒性,改善皮肤屏障功能。
金黄色葡萄球菌(Staphylococcus aureus)存在于人体皮肤表面和毛孔中。一般驻留于皮肤的葡萄球菌不会在正常人身上引起疾病,但金黄色葡萄球菌即使对正常人也会引起疾病。特别是通过伤口部位侵入体内时往往发病。金黄色葡萄球菌的毒性因子(virulence factor)大致分为存在于细胞中的毒性因子、外部毒素(external toxin)和酶(enzyme)。存在于细胞中的毒性因子包括蛋白A、纤连蛋白结合因子、磷壁酸等。外部毒素有肠毒素、中毒休克综合征毒素-1(TSST-1)、α-溶血素(Hla)等,酶有血浆凝固酶(coagulase)、葡萄球菌激酶(staphylokinase)、蛋白酶(protease)、脱氧核糖核酸酶(DNase)、脂肪酶(lipase)等(微生物学百科)。具有上述特性的金黄色葡萄球菌起到致病菌作用,引起脓肿等各种表皮感染、食物中毒、肺炎、脑膜炎、败血症等。已知多种疾病诸如过敏性患者的皮肤,在皮肤屏障(skin barrier)损伤的状态下,金黄色葡萄球菌充分形成菌落(colony)和生物膜,由此导致的炎症反应和皮肤细胞损伤会进一步加剧症状。结果导致具有正常皮肤屏障者与不具有正常皮肤屏障者的皮肤微生物分布各异。
本发明的发明人发现,济州红网藻提取物对改善皮肤屏障功能有效,特别是对抑制金黄色葡萄球菌有效。因此,根据一实施例的组合物对于特别是因皮肤疾病而导致皮肤屏障损伤或弱化的皮肤,可以更有效改善并保持皮肤屏障功能,具有加强皮肤保湿力、防止皮肤问题和防止皮肤老化的效果。
另外,所述济州红网藻提取物可以保持皮肤微生物组均衡,从而改善皮肤屏障功能。
所述济州红网藻提取物可以使用水、有机溶剂或它们的混合溶剂、通过本行业公知的普遍使用的提取方法提取,例如,可以利用有机溶剂提取。
所述有机溶剂可以为选自由C1-C4的无水或含水乙醇、丙三醇、丙二醇、丁二醇、乙酸乙酯、己烷和三氯甲烷组成的组中的一种以上。
例如,可以使用所述济州红网藻的乙醇提取物。
所述提取物可以使用冷浸提取法、温浸提取法或热提取法等方法,可以利用普遍使用的提取设备、超声波粉碎提取器或分馏器。
所述制备的提取物可以通过过滤或浓缩或干燥而去除溶剂,具体地,所述过滤可以利用滤纸或减压过滤器,所述浓缩可以利用减压浓缩器,例如可以利用旋转蒸发器进行减压浓缩,所述干燥例如可以通过冷冻干燥法执行。
所述皮肤外用剂组合物除济州红网藻提取物外,根据使用方法和使用目的,还可以包含多种成分。
所述皮肤外用剂组合物可以制备成选自由护肤水、乳液、霜和粉组成的组中的一种以上剂型使用,但不限于此。
具体而言,所述皮肤外用剂组合物可以制备成由化妆水、凝胶、水溶性液体、霜、粉、水包油(O/W)型和油包水(W/O)型组成的组中的剂型使用。
根据一实施例的皮肤外用剂组合物可以用作化妆品组合物。由于由天然物质构成,即使经常使用也不会引起皮肤问题,并可以持续改善皮肤屏障功能,提供皮肤保湿、改善皱褶及防止老化等效果。所述化妆品组合物不限于制备成本领域常规制备的任何剂型,例如可以但不限于制备成溶液、悬浮液、乳浊液、糊状物、凝胶、霜、乳液、粉、肥皂、含表面活性剂的清洁剂、油、粉状粉底、乳液粉底、蜡粉底和喷雾等。更详细地,可以适用于制备功能性化妆品,例如化妆水、营养霜、保湿霜、精华、眼霜、乳液、面膜和精华等基础化妆品。另一方面,一实施例的化妆品组合物所包含的成分,除作为有效成分的所述济州红网藻提取物之外,还可以包含化妆品组合物中普遍使用的成分,例如可以包含诸如抗氧化剂、稳定剂、增溶剂、维生素、颜料和香料的常用辅助剂和载体。
根据一实施例的皮肤外用剂组合物可以用作用于改善皮肤屏障功能的医药部外品组合物。与上述化妆品组合物一样,所述医药部外品组合物也可以具有选自加强皮肤保湿、防止皮肤问题和防止皮肤老化中的一种以上用途。
本说明书中使用的术语“医药部外品”是指用于诊断、治疗、改善、减轻、处置或预防人或动物疾病目的的物品中作用比医药品轻微的物品,例如根据药事法,所谓医药部外品是指除用作医药品用途的物品之外的物品,包括用于人或动物疾病的治疗或预防的制品、对人体作用轻微或不直接作用的制品等。
所述医药部外品组合物用于改善皮肤屏障功能的目的,更详细地,用作加强皮肤保湿、防止皮肤问题和防止皮肤老化的目的,其剂型没有特殊限制,例如可以为柔肤水、营养化妆水、按摩霜、营养霜、敷料、面膜、片装面膜、凝胶或皮肤粘附型化妆品剂型的组合物,也可以是诸如乳液、软膏、凝胶、霜、贴片或喷雾剂的经皮给药剂型的组合物。
另一方面,所述医药部外品组合物除所述济州红网藻提取物之外,还可以根据需要追加配合诸如增稠剂、稳定剂、增溶剂、维生素、颜料和香料的常用的辅助剂和载体等。
根据另一实施例,提供一种含有济州红网藻(Martensia jejuensis)提取物作为有效成分的用于改善皮肤屏障功能的功能性食品组合物。所述功能性食品可以包括健康功能食品。与上述化妆品组合物一样,所述功能性食品组合物也可以具有选自加强皮肤保湿、防止皮肤问题和防止皮肤老化中的一种以上用途。
对于所述功能性食品组合物,功能性食品的种类没有特殊限制,例如可以为肉类、香肠、面包、巧克力、糖果类、零食类、点心类、比萨、拉面、口香糖类、乳制品、各种汤类、饮料、茶、饮剂、酒精饮料和维生素复合剂等,并且广义上可以包括所有的食物。
所述功能性食品组合物除所述济州红网藻提取物外,还可以在功能性食品组合物中包含普遍使用的成分,例如还可以包含营养剂、维生素、电解质、调味剂、着色剂、果胶酸及其盐、海藻酸及其盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂、丙三醇、乙醇、碳酸饮料中使用的碳酸化剂或它们的组合。
下面为了具体说明本发明而举出实验例和实施例进行详细说明。但是,本发明的实验例可以变形为多种不同形态,不能理解为本发明的范围限定于以下详细描述的实验例和实施例。本发明的实验例和实施例用于向本领域的普通技术人员更完整地说明本发明。
制备例1:济州红网藻提取物的制备
粉碎已干燥的济州红网藻全株,浸于2倍重量比的95%的乙醇中,在此状态下暴露于超声波装置(150w、30℃)30分钟。浸渍24小时后,经滤纸过滤,随后利用旋转减压浓缩机去除溶剂,从而制备了济州红网藻提取物。
实验例1:菌株、细胞株和培养条件
菌株使用金黄色葡萄球菌(S.aureus,ATCC 6538)作为皮肤有害菌,使用表皮葡萄球菌(S.epidermidis,ATCC 12228)作为有益菌,在胰酶大豆肉汤(TSB)中以37℃的温度条件培养,并用于实验。
将皮肤角质形成细胞HaCaT细胞在添加了10%FBS的无抗生素DMEM培养基中以37℃、5%CO2的条件培养,并用于实验。
实验例2:溶血活性抑制程度测量
为了测量济州红网藻提取物对金黄色葡萄球菌的溶血活性的抑制程度,利用兔血进行溶血试验(hemolysis assay)。
在进行与济州红网藻提取物相关的金黄色葡萄球菌的毒性相关实验之前,通过事先实验确认了济州红网藻提取物对金黄色葡萄球菌的最小抑菌浓度(MIC)为2㎎/μl以上。
在金黄色葡萄球菌1x106CFU/ml中,按100μg/ml、50μg/ml、25μg/ml的济州红网藻提取物浓度进行处理,在TSB培养基中培养24小时。将所培养的菌液离心分离,只取上清液,利用0.2μm的针头式过滤器过滤后用于实验。
将用PBS清洗3次的25μl的兔血和975μl的细菌培养上清液加入1.5ml的微管中,在37℃下培养1小时后,以5500g(重力加速度)的条件离心分离1分钟,得到200μl的上清液,将其转移至微孔板后,用酶标仪在540nm下测量吸光度。
如图1所示,在经一实施例的济州红网藻提取物处理的实验组中,确认了金黄色葡萄球菌培养液的溶血活性受到抑制。
实验例3:皮肤微生物调节效能评价
将在TSB中培养24小时的金黄色葡萄球菌(S.aureus)和表皮葡萄球菌(S.epidermidis)分别约1x106CFU/ml接种于新培养基中,与200μg/mL的济州红网藻提取物一同培养24小时。然后,将稀释107倍的培养液涂抹于TSA,计数金黄色葡萄球菌和表皮葡萄球菌的菌落(colony)数。
结果如图2所示,确认了在经一实施例的济州红网藻提取物处理的实验组中,相比未处理的对照组,作为有益菌的表皮葡萄球菌的比率增加,作为有害菌的金黄色葡萄球菌的比率减少。
实验例4:金黄色葡萄球菌毒性因子表达
进行实时PCR实验以确认金黄色葡萄球菌的毒性因子即α-溶血素(Hla)、凝集因子A/B(ClfA、ClfB)、纤连蛋白结合因子A/B(FnbA、FnbB)、蛋白A(SpA)、分选酶(SrtA)基因的mRNA表达抑制效果。
在金黄色葡萄球菌约1x106CFU/ml中,按200μg/ml、100μg/μl、50μg/μl的济州红网藻提取物浓度进行处理,随后培养24小时。24小时后回收菌落并提取RNA(TE缓冲液,100℃沸腾)。测量所提取的RNA浓度和纯度后,利用1μgRNA,使用cDNA合成试剂盒(Intron)合成cDNA后,使用SYBR green进行实时PCR。
结果如图3所示,确认了与未经济州红网藻提取物处理的对照组相比,在经济州红网藻提取物处理的实验组中,金黄色葡萄球菌的毒性因子Hla、ClfB、FnbA/B、SpA基因的mRNA表达减少。
实验例5:皮肤角质细胞保护效果
实施皮肤角质形成细胞(HaCaT)与金黄色葡萄球菌的共培养以确认基于济州红网藻提取物的皮肤细胞保护效果。
在24孔板中培养皮肤角质形成细胞直至充满底面的80%为止,按约1000CFU/孔进行金黄色葡萄球菌处理,共培养(co-culture)既定时间后,执行MTT实验以测量细胞存活率。
结果如图4所示,确认了相比未经金黄色葡萄球菌处理的皮肤角质形成细胞(K),在经金黄色葡萄球菌处理的皮肤角质形成细胞(K+S)中出现细胞凋亡,在经济州红网藻提取物处理的组中,金黄色葡萄球菌所致的细胞凋亡受到抑制。
根据上述实验结果,确认了根据一实施例的济州红网藻提取物是通过调节金黄色葡萄球菌的毒性从而具有预防皮肤屏障损伤效果的天然材料。
下面根据上述实验例的结果,示出利用济州红网藻提取物制备的多种剂型例。但是,本领域的普通技术人员应当理解,这些剂型例仅用于说明本发明,本发明的剂型不限于这些剂型例。
(剂型例1至3:制备含有济州红网藻提取物的化妆品组合物)
剂型例1:乳液(emulsion)
【表1】
成分名 | 实施例(重量%) |
硬脂酸 | 0.5 |
乙醇 | 10.0 |
凡士林 | 1.0 |
角鲨烷 | 2.5 |
液体石蜡 | 6.0 |
聚氧乙烯山梨糖醇酐单油酸酯 | 1.5 |
1,3-丁二醇 | 8.0 |
三乙醇胺 | 0.05 |
香料 | 0.2 |
防腐剂 | 适量 |
抗氧化剂 | 适量 |
济州红网藻提取物 | 0.05 |
纯化水 | 至100 |
剂型例2:柔肤水(skin toner)
【表2】
成分名 | 重量% |
丙三醇 | 5.0 |
1,3-丁二醇 | 3.0 |
乙醇 | 5.0 |
聚氧乙烯壬基苯基醚 | 0.5 |
香料 | 适量 |
防腐剂 | 适量 |
济州红网藻提取物 | 0.05 |
纯化水 | 至100 |
剂型例3:霜(cream)
【表3】
Claims (12)
1.一种包含济州红网藻(Martensia jejuensis)提取物作为有效成分的皮肤外用剂组合物。
2.根据权利要求1所述的皮肤外用剂组合物,其中,
所述济州红网藻提取物的浓度为12.5μg/ml至200μg/ml。
3.根据权利要求1所述的皮肤外用剂组合物,其中,
所述皮肤外用剂组合物用于预防皮肤屏障损伤。
4.根据权利要求1所述的皮肤外用剂组合物,其中,
相对于所述皮肤外用剂组合物总重量,包含所述济州红网藻提取物0.001重量%至10重量%。
5.根据权利要求1所述的皮肤外用剂组合物,其中,
所述济州红网藻提取物缓解金黄色葡萄球菌(Staphylococcus aureus)的毒性。
6.根据权利要求1所述的皮肤外用剂组合物,其中,
所述济州红网藻提取物保持皮肤微生物组均衡。
7.根据权利要求1所述的皮肤外用剂组合物,其中,
所述济州红网藻提取物利用水、有机溶剂或它们的混合物提取。
8.根据权利要求7所述的皮肤外用剂组合物,其中,
所述有机溶剂为选自C1-C4的无水或含水乙醇、丙三醇、丙二醇、丁二醇、乙酸乙酯、己烷和三氯甲烷中的一种以上。
9.根据权利要求1所述的皮肤外用剂组合物,其中,
所述皮肤外用剂组合物制备成选自由化妆水、凝胶、水溶性液体、霜、粉、水包油型和油包水型组成的组中的剂型。
10.根据权利要求1至9中任一项所述的皮肤外用剂组合物,其中,
所述皮肤外用剂组合物为化妆品组合物。
11.根据权利要求1至9中任一项所述的皮肤外用剂组合物,其中,
所述皮肤外用剂组合物为用于改善皮肤屏障功能的医药部外品组合物。
12.一种用于改善皮肤屏障功能的功能性食品组合物,包含济州红网藻(Martensiajejuensis)提取物作为有效成分。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0027448 | 2021-03-02 | ||
KR1020210027448A KR102293592B1 (ko) | 2021-03-02 | 2021-03-02 | 제주비단망사 추출물을 포함하는 피부 외용제 조성물 및 기능성 식품 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114984063A true CN114984063A (zh) | 2022-09-02 |
CN114984063B CN114984063B (zh) | 2023-12-15 |
Family
ID=77465654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210155151.9A Active CN114984063B (zh) | 2021-03-02 | 2022-02-21 | 皮肤外用剂组合物及功能性食品组合物 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102293592B1 (zh) |
CN (1) | CN114984063B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102605534B1 (ko) * | 2022-08-03 | 2023-11-24 | 박헌의 | 산삼배양근 배양 배지를 이용한 식용 달팽이용 사료 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105325460A (zh) * | 2010-02-25 | 2016-02-17 | 马罗内生物创新公司 | 伯克霍尔德氏菌属的分离细菌菌株及其农药代谢物 |
WO2018216744A1 (ja) * | 2017-05-23 | 2018-11-29 | 一丸ファルコス株式会社 | 乳酸菌を含有する化粧料、皮膚保護剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101510936B1 (ko) * | 2013-01-29 | 2015-04-10 | 제주대학교 산학협력단 | 비바리 비단망사 추출물을 유효성분으로 포함하는 자가면역질환 또는 염증질환의 예방 및 치료용 조성물 |
-
2021
- 2021-03-02 KR KR1020210027448A patent/KR102293592B1/ko active IP Right Grant
-
2022
- 2022-02-21 CN CN202210155151.9A patent/CN114984063B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105325460A (zh) * | 2010-02-25 | 2016-02-17 | 马罗内生物创新公司 | 伯克霍尔德氏菌属的分离细菌菌株及其农药代谢物 |
WO2018216744A1 (ja) * | 2017-05-23 | 2018-11-29 | 一丸ファルコス株式会社 | 乳酸菌を含有する化粧料、皮膚保護剤 |
Non-Patent Citations (3)
Title |
---|
JEONG CHAN KANG 等: "Reappraisal of nine species of Martensia (Delesseriaceae, Rhodophyta) reported from Korea based on morphology and molecular analyses", BOTANICA MARINA, vol. 58, no. 3, pages 151 * |
MI YEON YANG 等: "DNA barcoding of the funoran-producing red algal genus Gloiopeltis (Gigartinales) and description of a new species, Gloiopeltis frutex sp. nov.", J APPL PHYCOL, pages 1381 * |
丁兰平 等: "中国海洋红藻门新分类系统", 广西科学, vol. 22, no. 2 * |
Also Published As
Publication number | Publication date |
---|---|
KR102293592B1 (ko) | 2021-08-26 |
CN114984063B (zh) | 2023-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102293593B1 (ko) | 바다고리풀 추출물을 포함하는 피부 외용제 조성물 및 기능성 식품 | |
KR102194315B1 (ko) | 락토바실러스 람노서스 균주를 접종하여 발효시킨 병풀 발효 추출물을 포함하는 항산화용 또는 피부 마이크로바이옴 균형 유지용 화장료 조성물 | |
CN105451751B (zh) | 用于去除皮肤角质材料的、含有绿茶乳杆菌的组合物 | |
KR102119825B1 (ko) | 현미, 녹차 및 포공영 발효 추출물을 포함하는 피부 내 마이크로바이옴 균형 유지용 화장료 조성물 및 이의 제조 방법 | |
KR20110134151A (ko) | 혼합 균 배양물을 포함하는 피부 염증질환 개선제, 이를 포함하는 화장료 조성물 및 약제학적 조성물 | |
JP2023551278A (ja) | 皮膚障害の微生物治療のための方法及び組成物 | |
KR20220004328A (ko) | 햄프씨드 오일을 포함하는 피부 내 마이크로바이옴 균형 유지용 조성물 | |
CN114984063B (zh) | 皮肤外用剂组合物及功能性食品组合物 | |
KR20170090997A (ko) | 락토바실러스 플란타룸을 포함하는 항진균용 조성물 | |
KR101433823B1 (ko) | 부챗말 추출물 또는 분획물을 이용한 피부 외용제 조성물 | |
TW201223559A (en) | Cytoprotective agent | |
KR102031359B1 (ko) | 영실 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 | |
KR20120117116A (ko) | 발효홍삼 추출물을 함유하는 피부세포 사멸방지용 화장료 조성물 | |
KR20190050364A (ko) | 호로파 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 | |
KR102031354B1 (ko) | 계지 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 | |
KR102492106B1 (ko) | 화장료 조성물 | |
KR102194314B1 (ko) | 락토바실러스 람노서스 균주를 접종하여 발효시킨 녹차 발효 추출물을 포함하는 항산화용 또는 피부 마이크로바이옴 균형 유지용 화장료 조성물 | |
KR102492105B1 (ko) | 화장료 조성물 | |
KR101436923B1 (ko) | 서시움 속 식물 추출물을 포함하는 항균용 구강 조성물 | |
KR20190050358A (ko) | 자화지정 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 | |
KR102031355B1 (ko) | 당귀 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 | |
KR102031361B1 (ko) | 정력자 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 | |
KR20190048885A (ko) | 의이인 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 | |
KR102031362B1 (ko) | 총백 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 | |
KR102031353B1 (ko) | 건율 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |